Literature DB >> 15939192

Imaging and response in soft tissue sarcomas.

Scott M Schuetze1.   

Abstract

Conventional CT and MRI scans provide exquisite anatomic detail of soft tissue sarcomas but fall short of estimating the degree of tumor viability within a sarcomatous mass. Functional imaging methods that measure biologic properties within sarcomas may be better able to determine true tumor responses to chemotherapy or radiotherapy. Many different approaches to measure biologic processes have been taken and are discussed, but positron emission tomography (PET) is currently the most quantitative and developed. A response in tumor glucose uptake, determined by PET, has been shown to correlate with improved clinical outcomes in high-grade extremity soft tissue sarcomas and gastrointestinal stromal tumors. Functional imaging of soft tissue sarcomas may prove to be useful clinically, therefore further investigation is warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15939192     DOI: 10.1016/j.hoc.2005.03.001

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  7 in total

1.  Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.

Authors:  Luis Paz-Ares; Antonio López-Pousa; Andrés Poveda; Carmen Balañá; Eva Ciruelos; Joaquim Bellmunt; Javier García del Muro; Mariano Provencio; Antonio Casado; Fernando Rivera-Herrero; Miguel Angel Izquierdo; Antonio Nieto; Adnan Tanović; Hernán Cortes-Funes; José María Buesa
Journal:  Invest New Drugs       Date:  2010-10-20       Impact factor: 3.850

2.  Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group.

Authors:  Abby R Rosenberg; James R Anderson; Elizabeth Lyden; David A Rodeberg; Suzanne L Wolden; Simon C Kao; David M Parham; Carola Arndt; Douglas S Hawkins
Journal:  Eur J Cancer       Date:  2013-12-18       Impact factor: 9.162

Review 3.  [Imaging of soft tissue sarcomas: standard approaches and new strategies].

Authors:  F Berger; E C Winkler; C Ruderer; M F Reiser
Journal:  Chirurg       Date:  2009-03       Impact factor: 0.955

4.  Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group.

Authors:  David A Rodeberg; Julie A Stoner; Andrea Hayes-Jordan; Simon C Kao; Suzanne L Wolden; Steve J Qualman; William H Meyer; Douglas S Hawkins
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

5.  Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial.

Authors:  Aaron R Weiss; Yen-Lin Chen; Thomas J Scharschmidt; Yueh-Yun Chi; Jing Tian; Jennifer O Black; Jessica L Davis; Julie C Fanburg-Smith; Eduardo Zambrano; James Anderson; Robin Arens; Odion Binitie; Edwin Choy; Justin W Davis; Andrea Hayes-Jordan; Simon C Kao; Mark L Kayton; Sandy Kessel; Ruth Lim; William H Meyer; Lynn Million; Scott H Okuno; Andrew Ostrenga; Marguerite T Parisi; Daniel A Pryma; R Lor Randall; Mark A Rosen; Mary Schlapkohl; Barry L Shulkin; Ethan A Smith; Joel I Sorger; Stephanie Terezakis; Douglas S Hawkins; Sheri L Spunt; Dian Wang
Journal:  Lancet Oncol       Date:  2020-07-20       Impact factor: 41.316

6.  In vivo molecular targeted radiotherapy.

Authors:  Ac Perkins
Journal:  Biomed Imaging Interv J       Date:  2005-10-01

Review 7.  Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin.

Authors:  Frédéric Amant; Domenica Lorusso; Alexander Mustea; Florence Duffaud; Patricia Pautier
Journal:  Sarcoma       Date:  2015-05-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.